Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here: https://rb.gy/09bxx

Investor relations Welcome to our investor section

Immunovia’s Presentation of Q1 Interim Report 2024, on April 29, 2024

View Report & Presentation
May 2024

Redeye Investor Forum

Listen to Immunovia CEO Jeff Borcherding’s presentation at Redeye Investor Forum.

See the presentation

Investors

The Share

The Immunovia AB share is, since 3 April 2018, traded on Nasdaq Stockholm. Immunovia has one class of shares. The Company has a registered share capital of SEK 1,131,579.05 allocated among 22,631,581 shares. The par value of the shares is SEK 0.05 per share.

Trading information
Ticker on Nasdaq Stockholm: IMMNOV
ISIN-code: SE0006091997
LEI-code: 549300KHWL6KK1XGUO81
The shares are registered by Euroclear Sweden.

Read more

IR Contact

If you have further questions, please contact our IR contact.

Read more

Subscribe

If you are interested in receiving our press releases and reports, please click on “Subscribe”.

Subscribe here